• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Rocket Pharmaceuticals Inc.

    5/16/25 4:13:14 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RCKT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001726398
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ROCKET PHARMACEUTICALS, INC.
    SEC File Number
    001-36829
    Address of Issuer
    350 FIFTH AVENUE
    SUITE 7530
    NEW YORK
    NEW YORK
    10118
    Phone
    646-440-9100
    Name of Person for Whose Account the Securities are To Be Sold
    Schwartz Jonathan David
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    158210326.5110773791905/16/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/14/2025Restricted Stock VestingIssuerCheckbox not checked158205/14/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Jonathan D. Schwartz
    9 Cedarbrook Drive
    Cranbury � NJ � 08512
    Common02/21/2025653269117.05

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    05/16/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Tyler Johnson, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan D. Schwartz

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $RCKT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RCKT

    DatePrice TargetRatingAnalyst
    5/30/2025$5.00Outperform → In-line
    Evercore ISI
    5/28/2025Overweight → Neutral
    Analyst
    5/28/2025$2.00Neutral → Sell
    Goldman
    5/28/2025$8.00Outperform → Market Perform
    Leerink Partners
    5/28/2025$2.50Buy → Hold
    Jefferies
    5/28/2025$7.00Overweight → Equal-Weight
    Morgan Stanley
    5/27/2025Buy → Hold
    TD Cowen
    5/27/2025Buy → Hold
    Needham
    More analyst ratings

    $RCKT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

      RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathy BAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene, leading to early-onset, progressive heart failure due to impaired cardiac function, high morbidity, and premature mortality Rocket plans to conduct a Phase 1 trial in the U.S. and is working towards the first patient treatment Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S

      6/30/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NodThera Announces Appointment of Elisabeth Björk as Board Member

      NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

      6/17/25 7:00:00 AM ET
      $PHVS
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

      Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c

      5/27/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rocket Pharmaceuticals downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Rocket Pharmaceuticals from Outperform to In-line and set a new price target of $5.00

      5/30/25 10:04:19 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Analyst

      Analyst downgraded Rocket Pharmaceuticals from Overweight to Neutral

      5/28/25 3:12:28 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals downgraded by Goldman with a new price target

      Goldman downgraded Rocket Pharmaceuticals from Neutral to Sell and set a new price target of $2.00

      5/28/25 9:38:28 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Patel Kinnari sold $4,944 worth of shares (767 units at $6.45), decreasing direct ownership by 0.17% to 441,927 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      5/22/25 4:05:43 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Schwartz Jonathan David sold $5,163 worth of shares (801 units at $6.45), decreasing direct ownership by 0.34% to 235,255 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      5/22/25 4:05:46 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Militello John sold $2,301 worth of shares (357 units at $6.45), decreasing direct ownership by 0.55% to 64,027 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      5/22/25 4:05:48 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Shah Gaurav bought $101,600 worth of shares (20,000 units at $5.08), increasing direct ownership by 3% to 792,680 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/14/25 6:57:31 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Patel Kinnari bought $99,165 worth of shares (21,099 units at $4.70) (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/10/25 4:07:53 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    SEC Filings

    See more
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      6/18/25 4:52:29 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

      SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      6/5/25 7:43:39 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ROCKET PHARMACEUTICALS, INC. (0001281895) (Filer)

      5/27/25 7:40:06 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Leadership Updates

    Live Leadership Updates

    See more
    • NodThera Announces Appointment of Elisabeth Björk as Board Member

      NodThera Announces Appointment of Elisabeth Björk as Board Member Former SVP at AstraZeneca R&D brings deep expertise in obesity and cardiometabolic research, portfolio strategy development and commercializationAppointment follows commencement of Phase 2 RESOLVE-1 trial of oral NLRP3 inflammasome inhibitor NT-0796 in patients with obesity Philadelphia, PA, June 17, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Elisabeth Björk, M.D., Ph.D. as Board Member. Elisabeth has more than 20 years of experience in late-stage cl

      6/17/25 7:00:00 AM ET
      $PHVS
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

      Enrollment completed in September and dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease Updated Phase 1 data from RP-A501 for Danon disease anticipated at American Heart Association's 2024 Late-Breaking Scientific Sessions Enrollment completed in low dose cohort of Phase 1 study of RP-A601 for PKP2-ACM; Preliminary data expected in the first half of 2025 Rolling BLA submission initiated for RP-L102 for Fanconi Anemia Progress on FDA-approval of KRESLADI for severe LAD-I; Approval anticipated in 2025 Appointed Mikael Dolsten, M.D., Ph.D., to Board of Directors Cash, cash equivalents and investments of approximately $235.7M; expected operational runway into 2026

      11/7/24 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

      Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience. "As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "His research and development experience will help advance our leading scientific capabilities and

      9/10/24 7:00:00 AM ET
      $PFE
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

      SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      12/16/24 7:51:51 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      11/8/24 10:52:38 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      4/5/24 9:47:13 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RCKT
    Financials

    Live finance-specific insights

    See more
    • Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

      Conference call to be held later today at 8:30 a.m. ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome. Rocket is conducting a comprehensive root cause analysis and remains in active dialogue with the U.S. Food and Drug Administration (FDA) and other key stakeholders, with the c

      5/27/25 7:00:00 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

      — Reported positive safety data at ASGCT from pediatric cohort of Phase 1 Danon Disease study that demonstrated RP-A501 was well-tolerated; efficacy update across pediatric as well as adult cohorts on track for late Q3 2022— — Announced top-line data at ASGCT from pivotal Phase 2 trial for severe LAD-I that showed RP-L201 was well-tolerated with 100% overall survival at one year; regulatory filings anticipated in first half of 2023 — — Primary endpoint met for Fanconi Anemia pivotal Phase 2 trial, FDA dialogue initiated for BLA planning; continued data readouts for Fanconi Anemia and Pyruvate Kinase Deficiency programs expected in Q4 2022 — — Achieved Current Good Manufacturing Practice

      8/8/22 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress

      — Continued to advance clinical gene therapy programs for the treatment of Danon Disease, Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) — — Updates on all four programs to be presented at the 2022 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) this month; trials on track for 2022 data readouts — — Appointed internationally recognized cardiovascular physician-scientist and biopharmaceutical executive Fady Malik, M.D., Ph.D., to Board of Directors – — Named experienced commercial leader Carlos Martin to Chief Commercial Officer and proven biotech executive Jessie Yeung to Vice President of Investor Relations and C

      5/5/22 4:01:00 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care